Home >> Research Area >>Metabolism>>PDE>> Pimobendan hydrochloride

Pimobendan hydrochloride

CAS# 77469-98-8

Pimobendan hydrochloride

Catalog No. BCC4175----Order now to get a substantial discount!

Product Name & Size Price Stock
Pimobendan hydrochloride: 5mg Please Inquire In Stock
Pimobendan hydrochloride: 10mg Please Inquire In Stock
Pimobendan hydrochloride: 20mg Please Inquire Please Inquire
Pimobendan hydrochloride: 50mg Please Inquire Please Inquire
Pimobendan hydrochloride: 100mg Please Inquire Please Inquire
Pimobendan hydrochloride: 200mg Please Inquire Please Inquire
Pimobendan hydrochloride: 500mg Please Inquire Please Inquire
Pimobendan hydrochloride: 1000mg Please Inquire Please Inquire
Related Products
  • IPI-145 (INK1197)

    Catalog No.:BCC1104
    CAS No.:1201438-56-3
  • IC-87114

    Catalog No.:BCC1161
    CAS No.:371242-69-2
  • PI-103

    Catalog No.:BCC1162
    CAS No.:371935-74-9
  • PIK-75

    Catalog No.:BCC1163
    CAS No.:372196-77-5
  • TGX-221

    Catalog No.:BCC1244
    CAS No.:663619-89-4

Quality Control of Pimobendan hydrochloride

Number of papers citing our products

Chemical structure

Pimobendan hydrochloride

3D structure

Chemical Properties of Pimobendan hydrochloride

Cas No. 77469-98-8 SDF Download SDF
PubChem ID 10126299 Appearance Powder
Formula C19H19ClN4O2 M.Wt 370.83
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in DMSO
Chemical Name 3-[2-(4-methoxyphenyl)-3H-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one;hydrochloride
SMILES CC1CC(=O)NN=C1C2=CC3=C(C=C2)N=C(N3)C4=CC=C(C=C4)OC.Cl
Standard InChIKey OJLOGBZTFKPHDQ-UHFFFAOYSA-N
Standard InChI InChI=1S/C19H18N4O2.ClH/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12;/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24);1H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Pimobendan hydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Pimobendan hydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Pimobendan hydrochloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.6967 mL 13.4833 mL 26.9665 mL 53.9331 mL 67.4163 mL
5 mM 0.5393 mL 2.6967 mL 5.3933 mL 10.7866 mL 13.4833 mL
10 mM 0.2697 mL 1.3483 mL 2.6967 mL 5.3933 mL 6.7416 mL
50 mM 0.0539 mL 0.2697 mL 0.5393 mL 1.0787 mL 1.3483 mL
100 mM 0.027 mL 0.1348 mL 0.2697 mL 0.5393 mL 0.6742 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Pimobendan hydrochloride

Pimobendan hydrochloride is a selective inhibitor of PDE3 with IC50 of 0.32 μM.

Featured Products
New Products
 

References on Pimobendan hydrochloride

Long-term Outcome of Irish Wolfhound Dogs with Preclinical Cardiomyopathy, Atrial Fibrillation, or Both Treated with Pimobendan, Benazepril Hydrochloride, or Methyldigoxin Monotherapy.[Pubmed:26936799]

J Vet Intern Med. 2016 Mar-Apr;30(2):553-9.

BACKGROUND: Dilated cardiomyopathy (DCM) is a common cause of morbidity and mortality in the Irish Wolfhound (IW). However, the benefit of medical treatment in IW dogs with preclinical DCM, atrial fibrillation (AF), or both has not been demonstrated. OBJECTIVES: Compare the time to develop congestive heart failure (CHF) or sudden death in IW dogs with preclinical DCM, AF, or both receiving monotherapy with pimobendan, methyldigoxin, or benazepril hydrochloride. ANIMALS: Seventy-five client-owned IW dogs. METHODS: Irish Wolfhound dogs were prospectively randomized to receive pimobendan (Vetmedin(R)), benazepril HCl (Fortekor(R)), or methyldigoxin (Lanitop(R)) monotherapy in a 1:1:1 ratio in a blinded clinical trial. The prospectively defined composite primary endpoint was onset of CHF or sudden death. To assure stringent evaluation of treatment effect, data from dogs complying with the study protocol were analyzed. RESULTS: Sixty-six IW fulfilling the study protocol included 39 males, 27 females; median (interquartile range) age, 4.0 years (3.0-5.0 years) and weight, 70.0 kg (63.0-75.0 kg). Primary endpoint was reached in 5 of 23 (21.7%) IW receiving pimobendan, 11 of 22 (50.0%) receiving benazepril HCl, and 9 of 21 (42.9%) receiving methyldigoxin. Median time to primary endpoint was significantly longer for pimobendan (1,991 days; 65.4 months) compared to methyldigoxin (1,263 days; 41.5 months; P = .031) or benazepril HCl-(997 days; 32.8 months; P = .008) treated dogs. CONCLUSIONS AND CLINICAL IMPORTANCE: In IW dogs with preclinical DCM, AF or both, pimobendan monotherapy significantly prolonged time to onset of CHF or sudden death than did monotherapy with benazepril HCl or methyldigoxin.

Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.[Pubmed:18638016]

J Vet Intern Med. 2008 Sep-Oct;22(5):1124-35.

BACKGROUND: Myxomatous mitral valve disease (MMVD) continues to be an important cause of morbidity and mortality in geriatric dogs despite conventional therapy. HYPOTHESIS: Pimobendan in addition to conventional therapy will extend time to sudden cardiac death, euthanasia for cardiac reasons, or treatment failure when compared with conventional therapy plus benazepril in dogs with congestive heart failure (CHF) attributable to MMVD. ANIMALS: Two hundred and sixty client-owned dogs in CHF caused by MMVD were recruited from 28 centers in Europe, Canada, and Australia. METHODS: A prospective single-blinded study with dogs randomized to PO receive pimobendan (0.4-0.6 mg/kg/d) or benazepril hydrochloride (0.25-1.0 mg/kg/d). The primary endpoint was a composite of cardiac death, euthanized for heart failure, or treatment failure. RESULTS: Eight dogs were excluded from analysis. One hundred and twenty-four dogs were randomized to pimobendan and 128 to benazepril. One hundred and ninety dogs reached the primary endpoint; the median time was 188 days (267 days for pimobendan, 140 days for benazepril hazard ratio = 0.688, 95% confidence limits [CL]=0.516-0.916, P= .0099). The benefit of pimobendan persisted after adjusting for all baseline variables. A longer time to reach the endpoint was also associated with being a Cavalier King Charles Spaniel, requiring a lower furosemide dose, and having a higher creatinine concentration. Increases in several indicators of cardiac enlargement (left atrial to aortic root ratio, vertebral heart scale, and percentage increase in left ventricular internal diameter in systole) were associated with a shorter time to endpoint, as was a worse tolerance for exercise. CONCLUSIONS AND CLINICAL IMPORTANCE: Pimobendan plus conventional therapy prolongs time to sudden death, euthanasia for cardiac reasons, or treatment failure in dogs with CHF caused by MMVD compared with benazepril plus conventional therapy.

Description

Pimobendan hydrochloride (UD-CG115 hydrochloride) is a selective inhibitor of PDE3 with IC50 of 0.32 μM.

Keywords:

Pimobendan hydrochloride,77469-98-8,Natural Products,PDE, buy Pimobendan hydrochloride , Pimobendan hydrochloride supplier , purchase Pimobendan hydrochloride , Pimobendan hydrochloride cost , Pimobendan hydrochloride manufacturer , order Pimobendan hydrochloride , high purity Pimobendan hydrochloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: